Thalamic nuclei in primary trigeminal neuralgia: gray matter volume patterns before and after surgery

Pashkov A.[1,2,3], Filimonova E.[1,2], Zaitsev B.[1], Martirosyan A.[1], Moysak G.[1,2,4], Rzaev J.[1,2,4]

[1] FSBI "Federal Center of Neurosurgery", Novosibirsk, Russia
[2] Department of neurosurgery, Novosibirsk State Medical University, Novosibirsk, Russia
[3] Department of Data Collection and Processing Systems, Novosibirsk State Technical University, Novosibirsk, Russia
[4] Department of Neuroscience, Institute of Medicine and Psychology, Novosibirsk State University, Novosibirsk, Russia

Abstract

Trigeminal neuralgia is a prevalent chronic pain disorder characterized by recurring episodes of intense facial pain, which significantly impairs patients' quality of life. MRI-based biomarkers have consistently demonstrated their ability to predict pain intensity and treatment outcomes. However, most studies have primarily focused on the trigeminal system, disregarding the extensive neural reorganization that occurs throughout the brain in response to chronic pain. In this study, we aimed to examine the thalamus, a key brain structure involved in information processing, and provide a detailed perspective on thalamic remodeling in response to chronic pain at the level of individual thalamic nuclei. We analyzed a sample of 61 patients with primary trigeminal neuralgia undergoing surgical treatment, along with 28 healthy participants. Our results revealed significant gray matter volume changes in thalamic nuclei among patients with trigeminal neuralgia. Notably, the intralaminar nuclei (centromedian/parafascicular) and nuclei associated with visual and auditory signal processing (lateral and medial geniculate bodies) exhibited significant alterations, contrasting with the ventral group nuclei involved in nociceptive processing. Additionally, we found no substantial volume increase in any of the studied nuclei following successful surgical intervention. The volumes of thalamic nuclei were negatively correlated with pain intensity and disease duration, while positively correlated with working memory scores. The findings obtained in this study, albeit preliminary, have promising clinical implications as they unveil previously unknown facets of chronic pain development and provide valuable guidance for clinical decision-making.

Introduction

Trigeminal neuralgia is a prevalent chronic pain disorder characterized by intermittent attacks of intense electric shock-like facial pain, ranging from a few seconds to several minutes in duration. The sharp and severe pain experienced by patients with classical trigeminal neuralgia is commonly attributed to vascular compression of the trigeminal nerve root, with the superior cerebellar artery being the most frequently implicated offending vessel [27]. Many patients with trigeminal neuralgia can effectively manage their pain by using tailored doses of antiepileptic drugs, tricyclic antidepressants, or combined norepinephrine-serotonin reuptake inhibitors, which have demonstrated clinical efficacy and relative safety in

pain management [17]. However, some patients may experience a loss of effectiveness of the prescribed medications in controlling the frequency or intensity of pain attacks over time. Although there are non-surgical therapeutic alternatives available, such as lidocaine and botulinum toxin injections or the implementation of transcranial magnetic stimulation protocols targeting specific brain regions like somatosensory, motor, and dorsolateral prefrontal cortices [48], surgical treatment remains one of the most effective approaches for alleviating trigeminal pain [29].

In clinical practice, modern neuroimaging protocols are routinely used to assess the presence and severity of neurovascular conflict and evaluate microstructural changes in the trigeminal nerve [47]. MRI-derived biomarkers have repeatedly demonstrated their ability to predict pain intensity and treatment outcomes [23]. However, most of these studies have focused solely on the trigeminal system, overlooking the fact that chronic pain leads to extensive neural reorganization throughout the brain [18,30]. Among the brain regions affected by prolonged pain experiences, the thalamus is frequently highlighted for its prominent role in sensory computations, including the processing of nociceptive signals. Recent publications have provided evidence of significant gray matter volume (GMV) reduction in the thalami of patients with trigeminal neuralgia [11,33,38,46]. Furthermore, the thalamus is increasingly recognized as a crucial hub not only for relaying neural signals to upstream areas but also for flexibly integrating diverse channels of incoming information based on the current environmental context and internal states [24,37]. Considering this perspective, a more nuanced understanding of thalamic involvement is necessary to comprehend both acute and chronic pain-related behavior.

However, previous studies examining changes in thalamic GMV have often treated the thalamus as a single entity, without delving into specific structural alterations at the level of individual nuclei. In our study, we aimed to advance this understanding by taking a more detailed approach and dividing the thalamus into 25 distinct nuclei. Our objective was to provide a finer-grained perspective on the remodeling of the thalamus in response to chronic pain, additionally focusing on the associations between gray matter alterations and patients' neuropsychological scores. Finally, we aimed to investigate whether these changes could be reversed following successful surgery.

Materials and methods

Patients and study design

This prospective study was conducted at our hospital from January 2022 to September 2023, and constituted a part of an ongoing scientific project dedicated to the comprehensive investigation of neuroimaging, neuropsychological, and blood biomarkers of chronic facial pain, as well as the search for predictors of surgical outcomes. The study included a total of 105 participants. Among them, there were 81 patients with a confirmed diagnosis of trigeminal neuralgia who were referred for surgical treatment due to the ineffectiveness or severe side effects of their pharmacological therapy (aged 27-83, 61% female). Additionally, a small number of patients (n=6) who were being managed conservatively on an outpatient basis at our Center were also included (aged 43-72, 67% female). Gender and age-matched healthy controls (n=30, aged 41-74, 57% female; HC) were recruited through local advertisements targeting hospital personnel.

The inclusion criteria for patients in this study were as follows: experiencing constant, episodic unilateral or bilateral pain in the innervation zone of the first and/or second and/or third branches of the trigeminal nerve; no contraindications for MRI; absence of intracranial structural anomalies and facial area anomalies (such as tumors, vascular malformations, and aneurysms) observed in neuroimaging data; absence of other neurological disorders (particularly migraines) and psychiatric disorders; MMSE score > 24 and right-handedness based on manual asymmetry profile. All patients with classical and idiopathic trigeminal neuralgia included in the study met the diagnostic criteria outlined in points 13.1.1.1 (Classical trigeminal neuralgia) and 13.1.1.3 (Idiopathic trigeminal neuralgia) of The International Classification of Headache Disorders, 3rd edition, 2018 (collectively referred to as primary trigeminal neuralgia, PTN). To minimize confounding factors, we specifically enrolled patients who met the criteria for these two nosological groups, excluding cases of trigeminal neuralgia secondary to multiple sclerosis, brain tumors, and other intracranial anomalies from consideration.

All selected patients and healthy controls underwent a series of diagnostic procedures, including brain MRI, as well as comprehensive neuropsychological and psychological assessment. Patients were additionally administered a number of clinical scales to estimate the levels of pain severity and potential postsurgical complications. The flowchart illustrating the patient selection process is depicted in Figure 1. Follow-up examination using the same protocol was conducted 6 months post-surgery.

All patients and healthy controls provided written informed consent to participate in the study, in accordance with the Declaration of Helsinki. Ethics approval for the research protocol was given by local ethic committee of Federal Center of Neurosurgery dated 25.05.21 (protocol # 7)

Figure 1. The flow diagram of the current study.

MRI acquisition

MR imaging data were acquired using a 3T system (Ingenia, Philips Healthcare, The Netherlands) equipped with a 16-channel receiver head coil. Brain magnetic resonance imaging included conventional sequences, as well as high-resolution 3D T1-WI (for morphometry) and high-resolution 3D T2-WI FFE with axial orientation (for detection and classification of neurovascular conflict). The total acquisition time was approximately 30 minutes. The T1-WI high-resolution sequence (3D TFE in the sagittal plane) had the following parameters: TR -– 6.56 ms, TE – 2.95 ms, FOV – 256*256 mm, flip angle - 8, matrix – 256*256, and slice thickness – 1 mm.

MRI data processing

Initially, conventional MRI data were analyzed by a neuroradiologist to find additional pathology not related to disease (such as prominent signs of small vessel disease, for example). Furthermore, cerebellopontine angle structures were visually evaluated with the 3D T2 FFE sequence in each case for the assessment of the presence and severity of neurovascular conflict, according to Sindou classification, as previously described [28].

Fully automatic surface-based MR morphometry of high-resolution T1-WI was performed with FreeSurfer v7.2.0 software (https://surfer.nmr.mgh.harvard.edu). Segmentation of the thalamic nuclei [25] was performed as part of the FreeSurfer 7.2.0 functional. The results were visually checked by the neuroradiologist for each subject.

Neurocognitive assessment

Neuropsychological testing was conducted using a specifically designed battery of tasks that encompassed key domains of executive functions, including attention, behavioral flexibility, working memory, short-term memory, and long-term memory for both verbal and nonverbal stimuli. The selection of tasks was based on a comprehensive review of the scientific literature, aiming to identify prior studies that demonstrated specific cognitive impairments in patients with chronic pain. The final version of the battery consisted of five tests: the mini mental state examination scale (MMSE), the Rey-Osterrieth complex figure, the Trail making test, the digit span task, and the verbal fluency task. A detailed description of all the neuropsychological tests utilized in the study can be found in the Supplementary file.

Pain assessment

To assess the severity of a patient's pain upon admission to the hospital and at the 6-month follow-up, two primary assessment tools were employed. The Brief Pain Inventory (BPI) utilizes a 10-point numerical rating scale and prompts patients to rate their minimal, maximal, and average pain intensity over the past week. Furthermore, the BPI evaluates the impact of pain on various aspects of the patient's daily activities and aids in distinguishing clinically significant pain features, such as tingling, burning, or numbness sensations.

In addition, the Barrow Neurological Institute Pain Intensity Score (BNIPS) assigns grades ranging from I to V, providing valuable insights into the medications used by patients and their effectiveness in pain management. Grade I is assigned to patients who report no

pain. Grade II is designated for patients experiencing occasional pain that does not require medication. Patients requiring prescribed medication for pain are classified as Grade III. Grade IV indicates inadequate pain control despite medication use. Finally, Grade V encompasses severe pain or lack of pain relief. For further analysis, we exclusively utilized the mean BPI score.

Statistical analysis

Continuous variables were reported as mean ± standard deviation if normally distributed and median (interquartile range, IQR) if distribution was different from normal. Normality of the distribution was checked with Shapiro-Wilk test. Categorical variables were presented with frequency and percentage. Chi-squared test was used for categorical data analysis. t-test with Welch correction was utilized for normally distributed data. Alternatively, we employed Mann-Whitney test when the normality assumption was violated. Comparison of measured variables in pre- vs post-surgery conditions in the same patients (paired sample) were done with Wilcoxon signed-rank test. In addition, homogeneity of variances in experimental groups were checked using a Levene test. We divided the group of patients with trigeminal neuralgia into two subgroups: those with right-sided pain and those with left-sided pain. Each subgroup was compared to a control group. One-way ANCOVA with post hoc Tukey tests was used to compare mean values of gray matter volumes between groups while controlling for age, gender and intracranial volume variables. To assess a relationship between brain and clinical as well as behavioral variables Spearman correlations were employed. p-value of 0.05 was considered a threshold for evaluating statistically significant results. False discovery rate (FDR) correction was applied to adjust the p-values under multiple comparison conditions. All p-values reported in the main text were FDR-adjusted. All statistical analyses were run in R (v. 4.3.1, 2023).

Results

Demographic and clinical data.

Total of 61 patients (33 female) and 28 healthy controls (16 female) were considered for the final analysis. Out of the initial sample of 81 patients, five participants were excluded due to multiple sclerosis, 14 patients had significant white matter lesions (Fazekas grades 2 or 3) and one patient dropped out as having bilateral pain. Two participants in the control group had Fazekas grade 2. The median age of the recruited patients was 59.5 (IQR = 12). Patients and healthy controls did not differ in age (U = 861, p = 0.83). Male and female patients did not differ in this variable as well (U = 570, p = 0.19). Similarly, PTN patients did not differ from the control group in body mass index (U = 605.5, p = 0.08). However, the statistically significant difference between groups in education years was identified (U = 1092.5, p = 0.008). Thirty seven patients (60%) had right-sided pain, twenty four patients (40%) suffered from left-sided pain. Median disease duration for the selected patients was 8 years (IQR = 6.4). This data is summarized in Table 1. Overwhelming majority of patients had BNIPS grades IV or V (89%). Median value of BPI average scores were 5 (IQR = 3) and this value increased up to 8 (IQR = 4) for the BPI max scores. Before surgery, the most commonly taken drug was carbamazepine (95%), followed by gabapentin (16%),

amitriptyline (8%) and pregabalin (5%). Neurovascular conflict of different grades was identified in 50 patients (81%). Fifty six patients from our sample underwent surgical intervention. Specifically, forty patients were subjected to microvascular decompression surgery (MVD; 64%), 10 patients underwent radiofrequency rhizotomy (RF; 16%) and balloon compression was performed on 6 patients (BC; 10%). Of these patients, 45 individuals (80%) were considered responders meaning that they were fully pain-free for at least six months post-surgery. 11 patients (20%) either did not respond to surgical treatment or surgery did not lead to full pain relief and demonstrated only partial effects.

	HC	PTN	p-value
Age, years	60 (5.5)	59.5 (12)	0.83
Sex, female	16	34	1
BMI, kg/m^2	26.95 (6.38)	28.4 (6.8)	0.08
Education, years	15 (3)	13 (3)	0.008

Table 1. Comparison of basic demographic and health-related variables between experimental and control groups.

Pain side	
Left	24 (38.7%)
Right	37 (59.7%)
Disease duration	8 (6.4)
BPI average	5 (3)
BPI max	8 (4)

BNIPS

III	4 (6.5%)
IV	51 (82.2%)
V	7 (11.3%)

Sindou grades

No compression	17 (28%)
Grade I	16 (26%)
Grade II	11 (18%)
Grade III	13 (21%)
Previous MVD	4 (7%)

Drugs

Carbamazepine	52 (84%)
Gabapentin	7 (11%)
Pregabalin	3 (5%)
Amitriptyline	3 (5%)
Oxcarbazepine/ lamotrigine	2 (3%)

| | NA | 2 (3%) |

Table 2. Major clinical variables in patients with PTN.

Grey matter volume alterations in thalamic nuclei

We used one-way ANCOVA with post hoc Tukey tests and FDR-correction for multiple comparisons to estimate GMV differences in 25 thalamic nuclei on each side between TN patients and healthy controls. Age, gender and intracranial volume variables were taken as covariates in the analysis. We revealed three clusters of nuclei showing significant differences between groups. First cluster consisted of intralaminar nuclei such as centromedial (CM), parafascicular (Pf) and paratenial (Pt) nuclei. Second cluster included lateral (LGN) and medial geniculate bodies (MGN) as well as thalamic nuclei belonging to the ventral group, mainly related to sensory processing. Third cluster was composed of so-called associative thalamic nuclei, namely, medial dorsal lateral (MDl), lateral dorsal (LD) and pulvinar nuclei. Patients with right-sided pain showed GMV reduction in centromedial (right thalamus: $t(83) = 3.2$, $p = 0.0056$; left thalamus: $t(83) = 2.62$, $p = 0.028$) and parafascicular (right thalamus: $t(82) = 2.9$, $p = 0.013$; left thalamus: $t(82) = 2.57$, $p = 0.031$) nuclei in both thalami. Group with left-sided facial pain showed no GMV reduction in CM and Pf ($p > 0.05$). Grey matter volumes of paratenial nuclei were lower in both right and left thalami of patients independent of pain side (right Pt - right-sided pain: $t(83) = 2.58$, $p = 0.03$; right Pt - left-sided pain: $t(83) = 2.57$, $p = 0.032$; left Pt - right-sided pain: $t(83) = 3.21$, $p = 0.005$; left Pt - left-sided pain: $t(83) = 2.12$, $p = 0.09$).

LGN and MGN nuclei concerned with visual and auditory signal processing, respectively, underwent the most pronounced GMV reductions in the PTN patients. Individuals with either side of pain demonstrated substantial alterations in both right and left lateral geniculate bodies (right LGN - right-sided pain: $t(82) = 3.94$, $p < 0.001$; right LGN - left-sided pain: $t(82) = 3.06$, $p = 0.008$; left LGN - right-sided pain: $t(82) = 4.63$, $p < 0.001$; left LGN - left-sided pain: $t(82) = 2.85$, $p = 0.015$). Analysis of MGN's volumes displayed significant differences between groups only in the left MGN (right-sided pain: $t(83) = 3.74$, $p = 0.001$; left-sided pain: $t(83) = 3.36$, $p = 0.003$). Among the ventral group of nuclei processing somatosensory signals, left ventral lateral posterior (VLp) and ventral posterolateral (VPL) nuclei showed a pronounced decrease in GMV in patients having right-sided pain (VLp: $t(81) = 2.67$, $p = 0.025$; VPL: $t(82) = 2.77$, $p = 0.019$, respectively).

In addition, right anterior (PuA) and medial pulvinar (PuM) regions were also characterized by GMV reduction in PTN patients (PuA - right-sided pain: $t(82) = 2.48$, $p = 0.04$; PuA - left-sided pain: $t(82) = 2.46$, $p = 0.042$; PuM - right-sided pain: $t(82) = 3.04$, $p = 0.009$; PuM - left-sided pain: $t(82) = 3.9$, $p < 0.001$). Left pulvinar regions in patients did not show any differences from the control group's ones ($p > 0.05$). Volume reduction was also evident in associative right LD and MDl nuclei (LD - left-sided pain: $t(82) = 2.6$, $p = 0.029$; MDl - right-sided pain: $t(82) = 2.79$, $p = 0.018$). Differences in GMV of individual thalamic nuclei between patients with right- and left-sided pain were not statistically significant for all above-mentioned comparisons ($p > 0.05$). The visualization of thalamic nuclei, which exhibited statistically significant differences compared to the control group, for patients with right-sided and left-sided pain is presented in Figure 2. The results of the comparison

between a single group of patients with trigeminal neuralgia, without stratification based on the presence of right- or left-sided pain, and healthy controls are provided in the Supplementary file.

Figure 2. Panel A. Reconstruction of thalamic nuclei showing significant differences between patients with right-sided pain and healthy controls. Panel B. Visualization of nuclei whose volumes differed significantly between patients with left-sided pain and control group's individuals. In both cases the size of depicted nuclei was larger in healthy participants. Paratenial nuclei are not shown due to their small size. CM - centromedian nucleus, LGN - lateral geniculate nucleus, MDl - mediodorsal lateral nucleus, MGN - medial geniculate nucleus, Pf - parafascicular nucleus, PuA - anterior pulvinar nucleus, PuM - medial pulvinar nucleus, VLp - ventral lateral posterior nucleus, VPL - ventral posterolateral nucleus.

Follow-up MRI study

MRI data of 29 patients collected 6 months after surgery was used for the follow-up morphometric analysis of thalamic nuclei. To ensure reliability of results, we first checked whether all differences detected between groups at the preceding stage were retained on a subsample of smaller size (n = 34). Volumes of left Pf (W = 605, p = 0.11) and right LD (W = 616, p = 0.13), MDl (W = 636, p = 0.15), PuA (W = 620, p = 0.07), VLp (W = 624, p = 0.13) were found to be statistically indistinguishable from those of controls. Among the nuclei that did differ between groups, none displayed an increase in GMV 6 months after surgical intervention. Detailed information on all statistical comparisons is available in the Supplementary file.

Neuropsychological profiles

Patients and healthy controls did not differ in MMSE (U = 813, p = 0.98), Rey copy (U = 693, p = 0.86), Rey immediate recall (U = 770.5, p = 0.36), Rey delayed recall scores (U = 538, p = 0.36). Measures of working memory and attention were also unremarkable (WAIS-F: U = 650.5, p = 0.98; WAIS-B: U = 826.5, p = 0.09; TMT index: U = 502, p = 0.24). However, before multiple comparison testing WAIS backward scores differed between groups (p uncorrected = 0.03). Phonemic and category fluency scores were significantly lower in PTN

patients compared to controls (U = 932, p = 0.001; U = 833, p = 0.03, respectively). All comparison results are presented in Table 3.

Domain	Cognitive test	HC	TN	P_{corr}
Global	MMSE	29 (1.5)	29 (2)	0.98
Visuospatial abilities	Rey copy	48 (0.5)	48 (1)	0.86
Short-term memory	Rey immediate recall	36 (17)	30 (21)	0.36
Long-term memory	Rey delayed recall	35 (19)	27 (21.5)	0.36
Working memory	WAIS forward	6 (1)	6 (1)	0.98
Working memory	WAIS backward	5 (1)	4 (2)	0.09
Attention	Trail making test	1.5 (0.47)	1.64 (0.4)	0.24
Verbal fluency	Phonemic fluency test	17 (5)	13 (5)	**0.001****
Verbal fluency	Semantic fluency test	21 (12)	18 (12)	**0.03***

Table 3. Neuropsychological scores of patients and controls.

Associations between morphometric, clinical and neuropsychological variables

We ran a correlational analysis to uncover relations between the extent of structural alteration of individual thalamic nuclei and a number of clinical variables like disease duration and pain intensity (taken as mean BPI score), as well as neuropsychological scores derived from patient's performance on the tests measuring memory, attention and cognitive flexibility. Disease duration showed low to moderate negative correlations with GMV in right/left LGN (r = -0.36, p = 0.046, CI95 = [-0.57, -0.11]; r = -0.32, p = 0.048, CI95 = [-0.53, -

0.06], respectively), right Pt (r = -0.35, p = 0.046, CI95 = [-0.56, -0.1]), right MDl (r = -0.31, p = 0.048, CI95 = [-0.53, -0.06]) and right VPL (r = -0.32, p = 0.048, CI95 = [-0.54, -0.07]), implying that the longer disease history was linked to smaller volumes of thalamic nuclei with preferential involvement of right thalamus. In a similar vein, pain intensity was negatively correlated with GMV in right/left CM (r = -0.38, p = 0.006, CI95 = [-0.58, -0.13]; r = -0.35, p = 0.01, CI95 = [-0.51, -0.09], respectively), right/left LGN (r = - 0.4, p = 0.006, CI95 = [-0.6, -0.15]; r = -0.41, p = 0.006, CI95 = [-0.61, -0.17], respectively), right MDl (r = -0.4, p = 0.006, CI95 = [-0.6, -0.15]), right/left Pf (r = -0.39, p = 0.006, CI95 = [-0.59, -0.14]; r = -0.38, p = 0.006, CI95 = [-0.58, -0.12], respectively), right Pt (r = -0.39, p = 0.006, CI95 = [-0.59, -0.14]), right PuA (r = -0.43, p = 0.006, CI95 = [-0.62, -0.18]), right PuM (r = -0.38, p = 0.006, CI95 = [-0.59, -0.13]), left VLp (r = -0.36, p = 0.008, CI95 = [-0.58, -0.11]) and VPL on both sides (r = -0.4, p = 0.006, CI95 = [-0.6, -0.15] for right VLP and r = -0.38, p = 0.006, CI95 = [-0.59, -0.13] for left VLP). In sum, pain intensity demonstrated a more pronounced relationship with thalamic GMV than disease duration both in number of nuclei involved and association's strength.

In contrast to above mentioned clinical variables, neuropsychological scores were positively associated with the volumes of thalamic nuclei. Working memory performance scores as measured by WAIS forward digit span task were moderately correlated with GMV in bilateral CM (r = 0.36, p = 0.032, CI95 = [0.08; 0.59]; r = 0.33, p = 0.045, CI95 = [0.04, 0.56], respectively), LGN (r = 0.36, p = 0.032, CI95 = [0.08, 0.59]; r = 0.36, p = 0.032, CI95 = [0.07, 0.59]), VLp (r = 0.39, p = 0.032, CI95 = [0.11, 0.61]; r = 0.38, p = 0.032, CI95 = [0.1, 0.61]), Pt (r = 0.35, p = 0.032, CI95 = [0.07, 0.58]; r = 0.32, p = 0.046, CI95 = [0.03, 0.56]) and VLP (r = 0.37, p = 0.032, CI95 = [0.09, 0.6]; r = 0.35, p = 0.034, CI95 = [0.06, 0.58]). WAIS backward digit span scores showed the same trend of associations in bilateral CM (r = 0.39, p = 0.04, CI95 = [0.12, 0.61]; r = 0.36, p = 0.04, CI95 = [0.08, 0.59]), Pt (r = 0.34, p = 0.04, CI95 = [0.06, 0.57]; r = 0.35, p = 0.04, CI95 = [0.07, 0.58]), VLp (r = 0.34, p = 0.04, CI95 = [0.05, 0.58]; r = 0.39, p = 0.04, CI95 = [0.1, 0.61]), VLP (r = 0.35, p = 0.04, CI95 = [0.07, 0.59]; r = 0.32, p = 0.045, CI95 = [0.04, 0.56]) and right PuA (r = 0.33, p = 0.045, CI95 = [0.04, 0.57]). Figure 3 shows the main results of correlation analysis described above.

Additionally, we sought to characterize the influence of drug intake on measured variables. Specifically, for this analysis, we selected only those patients who were taking carbamazepine as a sole medicine. We found that the dose of carbamazepine did not correlate significantly with GMV in thalamic nuclei and patient's neuropsychological performance scores (p > 0.05).

Figure 3. Correlation matrix displaying relationships between clinical, neuropsychological and morphometric variables. Color gradients are used to signify a direction and strength of associations with white color being indicative of null correlations, red and blue extremes of the gradient representing positive and negative correlations, respectively.

Discussion

Structural remodeling of thalamic nuclei has been shown to take place in a wide range of brain disorders [14]. Results of our previous study showed fractional anisotropy decrease in thalami of patients with primary TN [15]. In this study, we for the first time investigated thalamic nuclei in patients with chronic TN and demonstrated that they underwent significant structural alterations over the course of disease. Besides, we were able to estimate the relationship between volumes of individual thalamic nuclei and a number of clinical and neuropsychological variables. In doing so, we found that CM and Pf nuclei, being an integral part of the intralaminar group, LGN, MGN, VPL, which belong to the sensory cluster, VLp involved in the motor processing and associative PuA and PuM demonstrated the most noticeable alterations in their gray matter volumes.

CM-Pf complex, along with some nuclei of ventral group, including VLp, represents one of the major thalamic recipients of abundant afferents originating in basal ganglia and has long been known to be an effective target of deep brain stimulation in patients with intractable movement disorders and disorders of consciousness [26,44]. It has also previously been shown in a number of early and more recent papers that CM-Pf stimulation can help to successively mitigate intense chronic pain in some patients [1]. Alternatively, a stereotactic radiosurgery technique, medial thalamotomy, targeting CM-Pf also holds promise due to its pain-alleviating effects [16]. Importantly, the CM-Pf nuclei extensively innervate primary and secondary cortical motor areas. Transcranial stimulation of the motor cortex has emerged as another safe and effective option for managing otherwise untreatable pain, as supported by a series of clinical trials conducted in the past decade [34]. Anterior

pulvinar, which projects widely to sensorimotor cortical areas and medial frontal gyrus was also shown to be structurally altered in our patients and may be involved not only in the action planning and executing domains, but also in higher-order cognitive functions [4,19]. Furthermore, it is now recognized that post-stroke lesions of anterior pulvinar frequently manifest themselves in the form of intense pain [40]. The involvement of brain motor areas observed in patients suffering chronic pain may stem from the fact that they are often forced to restrict their movements and learn to act differently in order not to provoke or exacerbate pain. Consistent with this trend, studies focusing on patients with trigeminal neuralgia have also reported noticeable structural changes occurring in motor-related areas of these individuals [12, 36].

Unlike the currently emerging interest in studying the motor side of pain experience, the sensory component of pain has always been a main focus of investigation in individuals with chronic pain. Earlier studies have consistently demonstrated the GMV changes in brain regions involved in nociceptive processing, including thalamic nuclei [42]. In line with these findings, our own results point to the reduction of gray matter volume in ventral posterolateral nucleus (VPL), which is believed to be engaged in processing of incoming nociceptive afferents and relaying them to upstream somatosensory cortical regions. This finding can be interpreted as a compensatory strategy employed to cope with a significantly augmented influx of pain signals [33]. In addition, we were able to detect even more pronounced differences in volumes of lateral and medial geniculate bodies between groups. To the best of our knowledge, this is the first direct evidence for deep neural reorganization that takes place at the level of sensory thalamus in patients with PTN. The shift in this subtle balance between visual, auditory and nociceptive processing in case of chronic pain might be driven by redistribution of priority given to each of the sensory modalities due to the heightened salience of pain signals. The indirect corroboration of this hypothesis comes from studies demonstrating that CM-Pf, which exhibited shrinkage in our patients, might also be implicated in attention switching and reorienting toward salient objects or scenes [6,32]. However, in our study all thalamic nuclei that differed between PTN and HC groups were reduced in volume in a sample of patients and we did not find any conclusive evidence for the enlargement of nuclei involved in nociceptive processing.

Since pain is a complex biological phenomenon commonly defined as having tightly interwoven sensory, affective and cognitive components, another viable alternative may be that this reduction of LGN and MGN is secondary to alterations of brain areas concerned with affective processing. For instance, prior studies by Apkarian and colleagues convincingly demonstrated preferential recruitment of limbic regions as opposed to somatosensory areas during fMRI sessions in patients with chronic pain [3]. Moreover, these regions were also subject to considerable gray matter volume loss [21, 41]. There is also substantial evidence indicating a high prevalence of anxiety and depression among patients suffering from chronic trigeminal neuralgia [9]. Recent discoveries have highlighted the significant structural and functional changes that can occur in visual and auditory brain areas, which are directly connected to the LGN and MGN, as a result of comorbid conditions [10, 31]. Notably, the medial pulvinar, which exhibits gray matter volume reduction in patients with trigeminal neuralgia, is particularly implicated in various functional domains associated with emotional processing. It is known to receive dense afferents from the amygdala, hippocampus, posterior insula, anterior and posterior cingulate cortex, as well as from extensive regions of the frontal and parietal lobes [35]. Lesions involving the medial pulvinar commonly manifest as selective or more generalized impairments in emotional recognition and expression [7, 43]. Recent studies have further demonstrated the

involvement of the medial pulvinar in regulating arousal, which varied in response to nociceptive stimulation [5]. Interestingly, surgical intervention known as pulvinotomy has been found to result in a noticeable reduction in pain intensity and improved quality of life [45].

In this study, we were also able to find that patients with different pain sides diverged in terms of the number of thalamic nuclei showing marked differences from controls. Volume reduction was restricted to paratenial, laterodorsal, anterior and medial pulvinar, as well as lateral and medial geniculate nuclei in individuals with left-sided pain. In contrast, patients with right-sided pain were characterized by an additional drop of GMV in CM-Pf, MDI, VPL. LD size was not significantly different from that of healthy participants. Henssen and colleagues previously hypothesized an existence of an ipsilateral pathway for transmission of nociceptive information, alongside the well-known contralateral one [20]. Overall, a flux of nociceptive afferentation may not be symmetric for right and left sides of the body and strongly influenced by top-down regulation systems, including descending pain inhibitory system [39]. Overexcitation induced by an intensified stream of nociceptive signals might be a driving factor for gray matter loss in a range of thalamic nuclei. In addition, future studies are needed to ensure that these results are not just a consequence of the different number of patients in each of the groups.

In our sample, pain intensity and disease duration displayed negative correlations with volumes of nuclei. It is particularly noteworthy that the decrease of GMV in all thalamic nuclei was not reversed 6 months after surgical intervention implying that prolonged experience of pain may lead to a drastic and long-standing remodeling of established patterns of neural interactions. These findings also prompt the consideration of distinguishing between PTN-related structural changes and preexisting reorganized neural circuitries that may serve as risk factors for the transition from acute to chronic pain in patients with predispositions.

Patients with chronic pain commonly showcase neuropsychological deficits across a number of domains [2,8]. We investigated the extent to which these domains were affected in patients with trigeminal neuralgia and found that only verbal fluency scores differed between experimental groups. Moreover, they were positively correlated with gray matter volumes in some affected thalamic nuclei, although the strength of these correlations was generally moderate at best. Verbal fluency performance heavily relies on executive functions, which are frequently impaired in chronic pain and can contribute to less favorable treatment outcomes [13,22]. Further investigations are necessary to comprehensively explore the complex bidirectional relationship between pain and cognition.

Taken together, these findings have promising clinical implications for uncovering previously unknown details regarding chronic pain development and guiding clinical decision-making. However, it is worthwhile to mention several limitations of this study. First, we were unable to detect a statistically significant impact of carbamazepine intake on thalamic nuclei gray matter volume and cognitive functions in patients, despite subjective reports of memory decline and difficulties in attention focusing by the patients. This issue should be further studied systematically and in greater depth in future research. Second, current study design does not allow us to rule out the possibility that observed structural alterations in thalamic nuclei were secondary to that of in the basal ganglia or cortex. Future prospective longitudinal studies are required to address this issue. Finally, several investigated nuclei that showed statistically significant differences between groups during pre-surgical assessment, did not considerably differ at the 6 months follow-up on a smaller

sample, which implies that caution should be taken when using these results to inform clinical decisions.

References

1. Abdallat M, Saryyeva A, Blahak C, Wolf ME, Weigel R, Loher TJ, Runge J, Heissler HE, Kinfe TM, Krauss JK. Centromedian–Parafascicular and Somatosensory Thalamic Deep Brain Stimulation for Treatment of Chronic Neuropathic Pain: A Contemporary Series of 40 Patients. Biomedicines. 2021; 9(7):731.
2. Baker KS, Gibson SJ, Georgiou-Karistianis N, Giummarra MJ. Relationship between self-reported cognitive difficulties, objective neuropsychological test performance and psychological distress in chronic pain. Eur J Pain. 2018 Mar;22(3):601-613.
3. Baliki MN, Apkarian AV. Nociception, Pain, Negative Moods, and Behavior Selection. Neuron. 2015 Aug 5;87(3):474-91.
4. Barron DS, Eickhoff SB, Clos M, Fox PT. Human pulvinar functional organization and connectivity. Hum Brain Mapp. 2015 Jul;36(7):2417-31.
5. Bastuji H, Cadic-Melchior A, Ruelle-Le Glaunec L, Magnin M, Garcia-Larrea L. Functional connectivity between medial pulvinar and cortical networks as a predictor of arousal to noxious stimuli during sleep. Eur J Neurosci. 2023 Mar 8.
6. Beck AK, Sandmann P, Dürschmid S, Schwabe K, Saryyeva A, Krauss JK. Neuronal activation in the human centromedian-parafascicular complex predicts cortical responses to behaviorally significant auditory events. Neuroimage. 2020 May 1;211:116583.
7. Benarroch EE. Pulvinar: associative role in cortical function and clinical correlations. Neurology. 2015 Feb 17;84(7):738-47.
8. Berryman C, Stanton TR, Bowering KJ, Tabor A, McFarlane A, Moseley GL. Do people with chronic pain have impaired executive function? A meta-analytical review. Clin Psychol Rev. 2014 Nov;34(7):563-79.
9. Chang B, Zhu W, Li S. Effects of Depression and Anxiety on Microvascular Decompression Outcome for Trigeminal Neuralgia Patients. World Neurosurg. 2019 Aug;128:e556-e561.
10. Chen Y, Cui Q, Fan YS, Guo X, Tang Q, Sheng W, Lei T, Li D, Lu F, He Z, Yang Y, Hu S, Deng J, Chen H. Progressive brain structural alterations assessed via causal analysis in patients with generalized anxiety disorder. Neuropsychopharmacology. 2020 Sep;45(10):1689-1697.
11. Danyluk H, Andrews J, Kesarwani R, Seres P, Broad R, Wheatley BM, Sankar T. The thalamus in trigeminal neuralgia: structural and metabolic abnormalities, and influence on surgical response. BMC Neurol. 2021 Jul 24;21(1):290.
12. Desouza DD, Moayedi M, Chen DQ, Davis KD, Hodaie M. Sensorimotor and Pain Modulation Brain Abnormalities in Trigeminal Neuralgia: A Paroxysmal, Sensory-Triggered Neuropathic Pain. PLoS One. 2013 Jun 18;8(6):e66340.
13. Edwards RR, Dworkin RH, Sullivan MD, Turk DC, Wasan AD. The Role of Psychosocial Processes in the Development and Maintenance of Chronic Pain. J Pain. 2016 Sep;17(9 Suppl):T70-92.
14. Elvsåshagen T, Shadrin A, Frei O, van der Meer D, Bahrami S, Kumar VJ, Smeland O, Westlye LT, Andreassen OA, Kaufmann T. The genetic architecture of the human

thalamus and its overlap with ten common brain disorders. Nat Commun. 2021 May 18;12(1):2909.

15. Filimonova A, Pashkov A, Moysak G, Martirosyan A, Zaitsev B, Rzaev J. Diffusion tensor imaging reveals distributed white matter abnormalities in primary trigeminal neuralgia: tract-based spatial statistics study. Clin Neurol Neurosurg. 2023 Dec; 108080.

16. Franzini A, Rossini Z, Moosa S, Tropeano MP, Milani D, Attuati L, Clerici E, Navarria P, Pessina F, Picozzi P. Medial thalamotomy using stereotactic radiosurgery for intractable pain: a systematic review. Neurosurg Rev. 2022 Feb;45(1):71-80.

17. Gambeta E, Chichorro JG, Zamponi GW. Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments. Mol Pain. 2020 Jan-Dec;16:1744806920901890.

18. Ge X, Wang L, Pan L, Ye H, Zhu X, Fan S, Feng Q, Du Q, Yu W, Ding Z. Alteration of the cortical morphology in classical trigeminal neuralgia: voxel-, deformation-, and surface-based analysis. J Headache Pain. 2023 Feb 21;24(1):17.

19. Guedj C, Vuilleumier P. Functional connectivity fingerprints of the human pulvinar: Decoding its role in cognition. Neuroimage. 2020 Nov 1;221:117162.

20. Henssen DJ, Kurt E, Kozicz T, van Dongen R, Bartels RH, van Cappellen van Walsum AM. New Insights in Trigeminal Anatomy: A Double Orofacial Tract for Nociceptive Input. Front Neuroanat. 2016 May 10;10:53.

21. Henssen D, Dijk J, Knepflé R, Sieffers M, Winter A, Vissers K. Alterations in grey matter density and functional connectivity in trigeminal neuropathic pain and trigeminal neuralgia: A systematic review and meta-analysis. Neuroimage Clin. 2019;24:102039.

22. Higgins DM, Martin AM, Baker DG, Vasterling JJ, Risbrough V. The Relationship Between Chronic Pain and Neurocognitive Function: A Systematic Review. Clin J Pain. 2018 Mar;34(3):262-275.

23. Hung PS, Noorani A, Zhang JY, Tohyama S, Laperriere N, Davis KD, Mikulis DJ, Rudzicz F, Hodaie M. Regional brain morphology predicts pain relief in trigeminal neuralgia. Neuroimage Clin. 2021;31:102706.

24. Hwang K, Bertolero MA, Liu WB, D'Esposito M. The Human Thalamus Is an Integrative Hub for Functional Brain Networks. J Neurosci. 2017 Jun 7;37(23):5594-5607.

25. Iglesias JE, Insausti R, Lerma-Usabiaga G, Bocchetta M, Van Leemput K, Greve DN, van der Kouwe A; Alzheimer's Disease Neuroimaging Initiative; Fischl B, Caballero-Gaudes C, Paz-Alonso PM. A probabilistic atlas of the human thalamic nuclei combining ex vivo MRI and histology. Neuroimage. 2018 Dec;183:314-326.

26. Ilyas A, Pizarro D, Romeo AK, Riley KO, Pati S. The centromedian nucleus: Anatomy, physiology, and clinical implications. J Clin Neurosci. 2019 May;63:1-7.

27. Lambru G, Zakrzewska J, Matharu M. Trigeminal neuralgia: a practical guide. Pract Neurol. 2021 Oct;21(5):392-402. doi: 10.1136/practneurol-2020-002782. Epub 2021 Jun 9. PMID: 34108244; PMCID: PMC8461413.

28. Leal PR, Hermier M, Souza MA, Cristino-Filho G, Froment JC, Sindou M. Visualization of vascular compression of the trigeminal nerve with high-resolution 3T MRI: a prospective study comparing preoperative imaging analysis to surgical findings in 40 consecutive patients who underwent microvascular decompression for trigeminal neuralgia. Neurosurgery. 2011 Jul;69(1):15-25.

29. Li Y, Yang L, Ni J, Dou Z. Microvascular decompression and radiofrequency for the treatment of trigeminal neuralgia: a meta-analysis. J Pain Res. 2019 Jun 28;12:1937-1945.

30. Liu H, Hou H, Li F, Zheng R, Zhang Y, Cheng J, Han S. Structural and Functional Brain Changes in Patients With Classic Trigeminal Neuralgia: A Combination of Voxel-Based Morphometry and Resting-State Functional MRI Study. Front Neurosci. 2022 Jun 29;16:930765.

31. Lu F, Cui Q, Huang X, Li L, Duan X, Chen H, Pang Y, He Z, Sheng W, Han S, Chen Y, Yang Y, Luo W, Yu Y, Jia X, Tang Q, Li D, Xie A, Chen H. Anomalous intrinsic connectivity within and between visual and auditory networks in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jun 8;100:109889.

32. Minamimoto T, Kimura M. Participation of the thalamic CM-Pf complex in attentional orienting. J Neurophysiol. 2002 Jun;87(6):3090-101.

33. Obermann M, Rodriguez-Raecke R, Naegel S, Holle D, Mueller D, Yoon MS, Theysohn N, Blex S, Diener HC, Katsarava Z. Gray matter volume reduction reflects chronic pain in trigeminal neuralgia. Neuroimage. 2013 Jul 1;74:352-8.

34. Rapisarda A, Ioannoni E, Izzo A, Montano N. What Are the Results and the Prognostic Factors of Motor Cortex Stimulation in Patients with Facial Pain? A Systematic Review of the Literature. Eur Neurol. 2021;84(3):151-156.

35. Rosenberg DS, Mauguière F, Catenoix H, Faillenot I, Magnin M. Reciprocal thalamocortical connectivity of the medial pulvinar: a depth stimulation and evoked potential study in human brain. Cereb Cortex. 2009 Jun;19(6):1462-73.

36. Shen S, Zheng H, Wang J, Guo W, Guo X, Ji H, Zhang S, Chen Y, Shi G. Gray matter volume reduction with different disease duration in trigeminal neuralgia. Neuroradiology. 2022 Feb;64(2):301-311.

37. Shine JM. The thalamus integrates the macrosystems of the brain to facilitate complex, adaptive brain network dynamics. Prog Neurobiol. 2021 Apr;199:101951.

38. Tsai YH, Yuan R, Patel D, Chandrasekaran S, Weng HH, Yang JT, Lin CP, Biswal BB. Altered structure and functional connection in patients with classical trigeminal neuralgia. Hum Brain Mapp. 2018 Feb;39(2):609-621.

39. Vanneste S, De Ridder D. Chronic pain as a brain imbalance between pain input and pain suppression. Brain Commun. 2021 Feb 16;3(1).

40. Vartiainen N, Perchet C, Magnin M, Creac'h C, Convers P, Nighoghossian N, Mauguière F, Peyron R, Garcia-Larrea L. Thalamic pain: anatomical and physiological indices of prediction. Brain. 2016 Mar;139(Pt 3):708-22.

41. Wang Y, Cao DY, Remeniuk B, Krimmel S, Seminowicz DA, Zhang M. Altered brain structure and function associated with sensory and affective components of classic trigeminal neuralgia. Pain. 2017 Aug;158(8):1561-1570.

42. Wang Y, Yang Q, Cao D, Seminowicz D, Remeniuk B, Gao L, Zhang M. Correlation between nerve atrophy, brain grey matter volume and pain severity in patients with primary trigeminal neuralgia. Cephalalgia. 2019 Apr;39(4):515-525.

43. Ward R, Calder AJ, Parker M, Arend I. Emotion recognition following human pulvinar damage. Neuropsychologia. 2007 Apr 9;45(8):1973-8.

44. Weigel R, Krauss JK. Center median-parafascicular complex and pain control. Review from a neurosurgical perspective. Stereotact Funct Neurosurg. 2004;82(2-3):115-26.

45. Whittle IR, Jenkinson JL. CT-guided stereotactic antero-medial pulvinotomy and centromedian-parafascicular thalamotomy for intractable malignant pain. Br J Neurosurg. 1995 Apr;9(2):195-200.
46. Wu M, Jiang X, Qiu J, Fu X, Niu C. Gray and white matter abnormalities in primary trigeminal neuralgia with and without neurovascular compression. J Headache Pain. 2020 Nov 25;21(1):136.
47. Xu R, Nair SK, Raj D, Materi J, So RJ, Gujar SK, Huang J, Blitz AM, Lim M, Sair HI, Bettegowda C. The Role of Preoperative Magnetic Resonance Imaging in Assessing Neurovascular Compression Before Microvascular Decompression in Trigeminal Neuralgia. World Neurosurg. 2022 Dec;168:e216-e222.
48. Yang S, Chang MC. Effect of Repetitive Transcranial Magnetic Stimulation on Pain Management: A Systematic Narrative Review. Front Neurol. 2020 Feb 18;11:114.

A   B

	CM left	CM right	LD right	LGN left	LGN right	MDI right	MGN left	MGN right	Pf left	Pf right	Pt left	Pt right	PuA right	PuM right	VLp left	VLp right	VPL left	VPL right
WAIS forward	0.33	0.36	0.2	0.36	0.36	0.21	0.13	0.02	0.11	0.22	0.32	0.35	0.3	0.29	0.38	0.39	0.35	0.37
WAIS backward	0.36	0.39	0.06	0.29	0.21	0.21	0.26	0.27	0.26	0.36	0.35	0.34	0.33	0.28	0.39	0.34	0.32	0.35
TMT index	-0.04	-0.05	0.3	-0.05	-0.04	0.14	0.09	0.09	-0.04	-0.07	-0.06	-0.05	0.03	0.01	-0.19	-0.06	-0.12	-0.08
Rey immediate recall	0.09	0.18	-0.07	0.16	0.18	0.04	0.12	-0.02	0.17	0.28	0.12	0.06	0.14	0.09	0.17	0.09	0.22	0.14
Rey delayed recall	0.17	0.29	-0.06	0.17	0.16	0.19	0.22	0.06	0.27	0.27	0.24	0.16	0.14	0.08	0.29	0.23	0.21	0.23
Rey copy	-0.15	-0.21	-0.15	-0.05	-0.15	-0.04	0.04	0.16	-0.06	-0.13	-0.1	-0.26	-0.07	-0.08	-0.21	-0.22	-0.1	-0.18
Pain intensity	-0.35	-0.38	-0.1	-0.41	-0.4	-0.4	-0.18	-0.15	-0.38	-0.39	-0.34	-0.39	-0.43	-0.38	-0.36	-0.31	-0.38	-0.4
Fluency letter	-0.01	0.09	0.12	-0.1	-0.17	0.07	-0.11	-0.11	0.14	0.07	0.01	-0.09	-0.16	-0.22	0.12	0.08	-0.01	0.009
Fluency category	0.2	0.23	-0.02	0.05	-0.08	-0.02	0.09	0.11	0.3	0.21	0.23	0.12	0.04	0.03	0.21	0.2	0.19	0.13
Disease duration	-0.24	-0.25	-0.02	-0.32	-0.36	-0.31	-0.2	-0.12	-0.21	-0.25	-0.25	-0.35	-0.23	-0.26	-0.15	-0.22	-0.18	-0.32

value